Enterococcus, an emerging pathogen

OBJECTIVE: To review the bacterial genus Enterococcus with respect to its epidemiology, specific infections in humans, mechanisms of resistance and tolerance, and antimicrobial treatment. DATA SOURCES: A MEDLINE search of English-language journal articles published from 1977 to 1992 was completed. Articles published prior to 1977 were identified through Index Medicus and from references appearing in the bibliographies of other journal articles. Information also was acquired from abstracts, personal communication with infectious disease specialists with active research in the area of enterococcal infection, and conference proceedings. STUDY SELECTION: In vitro data; animal models of enterococcal infection; case reports; and case-controlled, cohort, and randomized controlled trials in humans were evaluated for relevant information. DATA EXTRACTION: Studies were evaluated by their methodologic strength (e.g., randomized controlled trial), reporting of clinically relevant outcomes (e.g., clinical response to antimicrobial therapy), statistical analyses, and accountability of all patients who entered the study. DATA SYNTHESIS: The incidence of enterococcal infections has increased in recent years and enterococci are now the second most frequently reported nosocomial pathogens. Enterococcus faecalis is the pathogen responsible for most enterococcal infections seen today; it has been implicated as an important cause of endocarditis, bacteremia, urinary tract infections, and intraabdominal infections. CONCLUSIONS: Enterococcal infection is of particular concern clinically because of its resistance to several antibiotics. Controlled comparative clinical trials of antimicrobial therapy in humans are lacking for several enterococcal infections. Therefore, the recommendations for antimicrobial therapy presented in this review are guidelines that reflect our current understanding of antibiotics used for enterococcal infection.

This article has been cited by other articles:

				D. K Farver, D. D Hedge, and S. C Lee Ramoplanin: A Lipoglycodepsipeptide Antibiotic Ann. Pharmacother., May 1, 2005; 39(5): 863 - 868. [Abstract] [Full Text] [PDF]

				J. Sillanpaa, Y. Xu, S. R. Nallapareddy, B. E. Murray, and M. Hook A family of putative MSCRAMMs from Enterococcus faecalis Microbiology, July 1, 2004; 150(7): 2069 - 2078. [Abstract] [Full Text] [PDF]

				L. Dube, J. Caillon, C. Gras-Le Guen, C. Jacqueline, M.-F. Kergueris, J.-C. Granry, G. Potel, and D. Bugnon Simulation of Human Gentamicin Pharmacokinetics in an Experimental Enterococcus faecalis Endocarditis Model Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3663 - 3666. [Abstract] [Full Text] [PDF]

				I. T. Paulsen, L. Banerjei, G. S. A. Myers, K. E. Nelson, R. Seshadri, T. D. Read, D. E. Fouts, J. A. Eisen, S. R. Gill, J. F. Heidelberg, et al. Role of Mobile DNA in the Evolution of Vancomycin-Resistant Enterococcus faecalis Science, March 28, 2003; 299(5615): 2071 - 2074. [Abstract] [Full Text] [PDF]

				M. Vancanneyt, A. Lombardi, C. Andrighetto, E. Knijff, S. Torriani, K. J. Bjorkroth, C. M. A. P. Franz, M. R. Foulquie Moreno, H. Revets, L. De Vuyst, et al. Intraspecies Genomic Groups in Enterococcus faecium and Their Correlation with Origin and Pathogenicity Appl. Envir. Microbiol., March 1, 2002; 68(3): 1381 - 1391. [Abstract] [Full Text] [PDF]

				P. M. Schlievert, P. J. Gahr, A. P. Assimacopoulos, M. M. Dinges, J. A. Stoehr, J. W. Harmala, H. Hirt, and G. M. Dunny Aggregation and Binding Substances Enhance Pathogenicity in Rabbit Models of Enterococcus faecalis Endocarditis Infect. Immun., January 1, 1998; 66(1): 218 - 223. [Abstract] [Full Text] [PDF]

				C. M. Oliphant Therapeutic Drug Monitoring of Therapy for Infectious Diseases Journal of Pharmacy Practice, February 1, 1997; 10(1): 7 - 19. [Abstract] [PDF]

				C. M. Oliphant Therapeutic Drug Monitoring of Therapy for Infectious Diseases Journal of Pharmacy Practice, February 1, 1995; 8(1): 18 - 28. [Abstract] [PDF]